Comparison of Pirarubicin-based Versus Gemcitabine-docetaxel Chemotherapy for Relapsed and Refractory Osteosarcoma: a Single Institution Experience

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2012 Apr 27

PMID 22534798

Citations 13

Authors

Aina He

Weixiang Qi

Yujing Huang

Yuanjue Sun

Zan Shen

Hui Zhao

Yumei Yang

Yang Yao

Affiliations

Soon will be listed here.

Abstract

Background: The prognoses for patients with relapsed and refractory osteosarcoma are poor and the optimal treatment strategy is still to be defined. We conducted this retrospective study to compare the feasibility and efficacy of pirarubicin-based chemotherapy with gemcitabine-docetaxel combination regimens for the salvage of these patients.

Methods: The clinical data of 75 patients who received pirarubicin-based (n = 52) or gemcitabine-docetaxel (n = 23) chemotherapy as a second-line treatment for relapsed and refractory osteosarcoma between January 2005 and September 2011were reviewed retrospectively. Tumor response was evaluated every two chemotherapy cycles by computed tomography/magnetic resonance imaging (CT/MRI) scans using the Response Evaluation Criteria in Solid Tumors. Progression-free survival and overall survival (OS) were evaluated by Kaplan-Meier analysis. Toxicity was examined according to the National Cancer Institute Toxicity Criteria grading system.

Results: Patient characteristics were well balanced in the two groups. The response rate was 25.0 % in patients who received pirarubicin-based chemotherapy, while it was 13.0 % in the gemcitabine-docetaxel group. Moreover, the median OS was longer in the pirarubicin-based chemotherapy group (14.0 vs. 9.0 months, P < 0.05), especially in the pirarubicin-ifosfamide (14.0 months) and pirarubicin-cisplatin (15.0 months) subgroups. The incidence of grade 3-4 neutropenia was higher in the gemcitabine-docetaxel group (5.8 vs. 43.5 %, P < 0.05); other grade 3-4 toxicities were comparable in the two groups.

Conclusions: In our experience, pirarubicin-based chemotherapy was comparable with gemcitabine-docetaxel as a second-line treatment for relapsed and refractory osteosarcoma, and it even seemed to show greater efficacy, with milder toxicity. Further studies, especially prospective clinical trials, focusing on pirarubicin-based treatments for relapsed and refractory osteosarcoma patients should be strongly considered.

Citing Articles

The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre-clinical study.

Low K, Foulkes P, Hills F, Roberts H, Stordal B Cancer Med. 2024; 13(18):e70248.

PMID: 39315544 PMC: 11420655. DOI: 10.1002/cam4.70248.

Noncoding RNA PVT1 in osteosarcoma: The roles of lncRNA PVT1 and circPVT1.

Wu T, Ji Z, Lin H, Wei B, Xie G, Ji G Cell Death Discov. 2022; 8(1):456.

PMID: 36379920 PMC: 9666356. DOI: 10.1038/s41420-022-01192-1.

Systematic Review of Recurrent Osteosarcoma Systemic Therapy.

Gazouli I, Kyriazoglou A, Kotsantis I, Anastasiou M, Pantazopoulos A, Prevezanou M Cancers (Basel). 2021; 13(8).

PMID: 33917001 PMC: 8067690. DOI: 10.3390/cancers13081757.

Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis.

Saito S, Aiba H, Yamada S, Okamoto H, Hayashi K, Kimura H BMC Cancer. 2020; 20(1):868.

PMID: 32907549 PMC: 7488346. DOI: 10.1186/s12885-020-07378-z.

Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation.

Yu D, Zhang S, Feng A, Xu D, Zhu Q, Mao Y Medicine (Baltimore). 2019; 98(19):e15582.

PMID: 31083238 PMC: 6531127. DOI: 10.1097/MD.0000000000015582.

References

Bhalla K . Microtubule-targeted anticancer agents and apoptosis. Oncogene. 2003; 22(56):9075-86. DOI: 10.1038/sj.onc.1207233. View

Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T . Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol. 2003; 163(3):1109-16. PMC: 1868274. DOI: 10.1016/S0002-9440(10)63470-0. View

Cortes E, HOLLAND J, Wang J, Sinks L, Blom J, Senn H . Amputation and adriamycin in primary osteosarcoma. N Engl J Med. 1974; 291(19):998-1000. DOI: 10.1056/NEJM197411072911903. View

Arndt C, Crist W . Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999; 341(5):342-52. DOI: 10.1056/NEJM199907293410507. View

Tabone M, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J . Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol. 1994; 12(12):2614-20. DOI: 10.1200/JCO.1994.12.12.2614. View

Ozaki T, Flege S, Kevric M, Lindner N, Maas R, Delling G . Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2003; 21(2):334-41. DOI: 10.1200/JCO.2003.01.142. View

Rodriguez-Galindo C, Daw N, Kaste S, Meyer W, Dome J, Pappo A . Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. J Pediatr Hematol Oncol. 2002; 24(4):250-5. DOI: 10.1097/00043426-200205000-00006. View

Friedman M, Carter S . The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol. 1972; 4(5):482-510. DOI: 10.1002/jso.2930040512. View

Shinozaki T, Watanabe H, Yanagawa T, Shirakura K, Takagishi K . Pirarubicin-based versus doxorubicin-based osteosarcoma chemotherapy. Ann Pharmacother. 2002; 36(6):996-9. DOI: 10.1345/aph.1A187. View

10.

Okuno S, Edmonson J, Mahoney M, Buckner J, Frytak S, Galanis E . Phase II trial of gemcitabine in advanced sarcomas. Cancer. 2002; 94(12):3225-9. DOI: 10.1002/cncr.10602. View

11.

Ferguson W, Goorin A . Current treatment of osteosarcoma. Cancer Invest. 2001; 19(3):292-315. DOI: 10.1081/cnv-100102557. View

12.

Ottaviani G, Jaffe N . The epidemiology of osteosarcoma. Cancer Treat Res. 2010; 152:3-13. DOI: 10.1007/978-1-4419-0284-9_1. View

13.

Geoerger B, Chisholm J, Le Deley M, Gentet J, Zwaan C, Dias N . Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study. Eur J Cancer. 2010; 47(2):230-8. DOI: 10.1016/j.ejca.2010.09.015. View

14.

Chen J, Horwitz S . Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. Cancer Res. 2002; 62(7):1935-8. View

15.

Saeter G, Hoie J, Stenwig A, Johansson A, Hannisdal E, SOLHEIM O . Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer. 1995; 75(5):1084-93. DOI: 10.1002/1097-0142(19950301)75:5<1084::aid-cncr2820750506>3.0.co;2-f. View

16.

Navid F, Reikes Willert J, McCarville M, Furman W, Watkins A, Roberts W . Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008; 113(2):419-25. DOI: 10.1002/cncr.23586. View

17.

Berger M, Massimo B, Grignani G, Giovanni G, Ferrari S, Stefano F . Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer. 2009; 115(13):2980-7. DOI: 10.1002/cncr.24368. View

18.

McTiernan A, Whelan J . A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma. Sarcoma. 2008; 8(2-3):71-6. PMC: 2395610. DOI: 10.1080/13577140410001711764. View

19.

Qi W, He A, Tang L, Shen Z, Yao Y . Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute. Med Oncol. 2011; 29(3):2229-33. DOI: 10.1007/s12032-011-0021-y. View

20.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View